Tvardi Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $204.1M | $21.4M |
| Jun 2022 | — | $204.4M | $46.7M |
| Sep 2022 | — | $184.8M | $42.8M |
| Dec 2022 | — | $158.8M | $63.7M |
| Mar 2023 | — | $136.6M | $47.4M |
| Jun 2023 | — | $108.9M | $58.2M |
| Sep 2023 | — | $85.6M | $62.9M |
| Dec 2023 | — | $-62.1M | $51.8M |
| Mar 2024 | — | $-66.2M | $47.0M |
| Jun 2024 | — | $-73.1M | $49.2M |
| Sep 2024 | — | $-78.5M | $37.1M |
| Dec 2024 | — | $-91.1M | $31.6M |
| Mar 2025 | — | $-100.6M | $34.2M |
| Jun 2025 | — | $32.9M | $20.6M |
| Sep 2025 | — | $27.9M | $21.4M |
| Dec 2025 | — | $20.9M | $20.7M |
| Mar 2026 | — | $14.5M | $19.9M |
| Jun 2026 | — | $8.4M | $15.8M |